A clinical research study for children and adolescents with Dravet syndrome looking to research how safe an investigational medication is.

Join a clinical study that is looking for a way to restore protein levels in children and teenagers with Dravet syndrome.

The MONARCH Study is looking at how safe a potential new medication (investigational medication) is in children and adolescents with Dravet syndrome, and what the body does to it.

The investigational medication is designed to restore the levels of a specific protein in the brain, called Na\(_{1.1}\), to normal. Na\(_{1.1}\) is important for the nerves in the brain to work properly. However, children and adolescents with Dravet syndrome have low levels of Na\(_{1.1}\) in their brain. Low levels of Na\(_{1.1}\) can lead to seizures and other symptoms of Dravet syndrome.

Your child may be able to take part if they:

- are between 2 and 18 years of age
- have been diagnosed with Dravet syndrome
- have taken at least 2 anti-epileptic medications previously that either did not work well enough or had to be stopped because of side effects
- are currently taking at least 1 anti-epileptic medication.

Your child will receive 1 dose of the investigational medication and have 1 overnight stay. The study will involve about 8 visits to the study center and 3 telephone calls. Your child will be in the study for about 7–9 months. If your child completes the study, they may be able to enter another study to continue to receive the investigational medication if they meet certain requirements.

Want to know more?

If you are interested in learning more about the MONARCH Study, please visit: [www.monarchstudy.com](http://www.monarchstudy.com)

You can also contact the MONARCH Study Team directly at: [monarch@iqvia.com](mailto:monarch@iqvia.com)